0.9387
前日終値:
$0.7987
開ける:
$0.82
24時間の取引高:
179.69K
Relative Volume:
0.84
時価総額:
$41.49M
収益:
-
当期純損益:
$-131.52M
株価収益率:
-0.5274
EPS:
-1.78
ネットキャッシュフロー:
$-107.56M
1週間 パフォーマンス:
+24.78%
1か月 パフォーマンス:
+32.10%
6か月 パフォーマンス:
-46.66%
1年 パフォーマンス:
-75.62%
Prelude Therapeutics Inc Stock (PRLD) Company Profile
名前
Prelude Therapeutics Inc
セクター
電話
(302) 467-1280
住所
175 INNOVATION BOULEVARD, WILMINGTON
PRLD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PRLD
Prelude Therapeutics Inc
|
0.9387 | 41.49M | 0 | -131.52M | -107.56M | -1.78 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-09-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
2024-06-20 | ダウングレード | Barclays | Equal Weight → Underweight |
2024-03-13 | 開始されました | JMP Securities | Mkt Outperform |
2024-02-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2022-11-21 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2022-07-29 | 開始されました | Jefferies | Buy |
2022-03-15 | ダウングレード | BofA Securities | Buy → Neutral |
2022-02-28 | ダウングレード | Barclays | Overweight → Equal Weight |
2021-10-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2021-07-27 | アップグレード | BofA Securities | Neutral → Buy |
2021-04-26 | 開始されました | H.C. Wainwright | Buy |
2021-03-09 | 開始されました | Barclays | Overweight |
2020-11-20 | ダウングレード | BofA Securities | Buy → Neutral |
2020-10-20 | 開始されました | BofA Securities | Buy |
2020-10-20 | 開始されました | Goldman | Neutral |
2020-10-20 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prelude Therapeutics Inc (PRLD) 最新ニュース
HC Wainwright Issues Positive Forecast for PRLD Earnings - Defense World
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know - MSN
Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech
Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com India
Prelude Therapeutics stock surges on insider buying - Investing.com
Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa
Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com Australia
Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com
Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa
PRLD stock touches 52-week low at $0.66 amid sharp annual decline - Investing.com
Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ - openPR.com
Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock By Investing.com - Investing.com Australia
Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock - Investing.com India
Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MyChesCo
Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase - Investing.com Australia
Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase By Investing.com - Investing.com South Africa
Prelude Therapeutics’ SWOT analysis: biotech stock faces mixed outlook amid clinical trials - Investing.com Australia
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial - MyChesCo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares By Investing.com - Investing.com South Africa
Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares - Investing.com
Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements - MyChesCo
Barclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD) - The Globe and Mail
Rhumbline Advisers Purchases 154,826 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Rhumbline Advisers Increases Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - The AM Reporter
Prelude Therapeutics Reports 2024 Financial Results - TipRanks
Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77) - TipRanks
Prelude Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Prelude Therapeutics Inc SEC 10-K Report - TradingView
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewswire
PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MyChesCo
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo
Prelude Therapeutics to Present at Barclays Global Healthcare Conference - MSN
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MyChesCo
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
How Will Prelude's Cancer Pipeline Updates Impact Investors at Upcoming Barclays Conference? - StockTitan
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MyChesCo
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Yahoo Finance
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN
PRLD stock touches 52-week low at $0.79 amid market challenges - Investing.com
Prelude Therapeutics Inc (PRLD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):